Prot# GS-US-193-0101: Multi-Center, Open-Label, Dose-Escalating Phase I/II Trial of GS-9219 Administered Once Every Three Weeks Intravenously to Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Non-Hodgkin's Lymphoma

Project: Research project

Project Details

StatusFinished
Effective start/end date2/25/082/25/11

Funding

  • Quintiles, Inc. (GS-US-193-0101)
  • Gilead Sciences, Inc. (GS-US-193-0101)